NEWS
Our Latest News
ARCHIMED acquires SeqCenter, a fast-growing player in cutting-edge DNA and RNA gene sequencing
SeqCenter is a category leader in Next-Generation Sequencing, which can sequence hundreds of thousands of genes in record-time and at low cost.
Global private equity healthcare specialist ARCHIMED announces the acquisition of Pittsburgh, Pennsylvania-based genetic sequencing provider SeqCenter. SeqCenter’s founding scientists initially worked at the University of Pittsburgh. Frustrated with the pace, cost and difficulty of obtaining sequencing data from existing vendors and academic core laboratories, they developed their own approach to gene sequencing, ultimately leaving academia and founding SeqCenter in 2019.
ARCHIMED’s NAMSA consolidates leadership in Medical Device Clinical Research, buying Clinlogix
August
2,
2021
ARCHIMED buys Stragen Pharma, a leader in the development, registration and distribution of hard-to-make generic drugs
June
24,
2021
ARCHIMED’s Fytexia buys B Natural, the European leader in the extraction and refinement of compounds produced by bees
June
1,
2021
ARCHIMED’s Direct Healthcare Group buys United Care BV
March
24,
2021
ARCHIMED’s Direct Healthcare Group acquires Talley
March
3,
2021
368